The proposed recommendations are intended to safely expedite approvals of promising therapies for multiple myeloma, but one expert is skeptical about the likelihood of industry compliance.

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or refractory multiple myeloma. In 2021, the FDA approved idecabtagene vicleucel (ide ...

Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at near ...

Many symptoms of multiple myeloma (MM) overlap with other conditions, including low back pain, diabetes, chronic kidney disease and arthritis. Renal insufficiency caused by MM can be difficult to ...

Multiple myeloma patients have a fivefold increased risk of infections compared to healthy controls, with sepsis and pneumonia being the most prevalent. The study found a 70% infection risk in MM ...

The initial diagnostic workup should include a history and physical examination, as well as some baseline laboratory studies (Figure 2-1). The initial diagnostic workup should include a history and ...

Are an adult with relapsed or refractory multiple myeloma Have tried at least four previous lines of treatments for multiple myeloma, including: Immune system modulators (help boost the immune system ...

How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...

Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...